NPI: 1497933162 · SAN DIEGO, CA 92127 · Clinical Medical Laboratory · NPI assigned 02/05/2008
Authorized official THOMAS, ROBERT controls 20+ related entities in our dataset. Read more
| Authorized Official | THOMAS, ROBERT (CHIEF FINANCIAL OFFICER) |
| NPI Enumeration Date | 02/05/2008 |
Other providers sharing the same authorized official: THOMAS, ROBERT
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 6,079,459 | $71.06M |
| 2019 | 8,371,034 | $82.35M |
| 2020 | 7,209,590 | $65.53M |
| 2021 | 2,397,548 | $64.78M |
| 2022 | 2,754,195 | $83.46M |
| 2023 | 2,139,251 | $113.00M |
| 2024 | 1,733,794 | $99.13M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1,813,365 | 947,184 | $152.24M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 993,030 | 522,631 | $130.03M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2,943,166 | 1,452,297 | $90.51M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1,093,441 | 617,117 | $76.60M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 898,069 | 452,131 | $43.33M |
| 80321 | 865,214 | 405,766 | $4.45M | |
| 80361 | 947,271 | 462,300 | $4.08M | |
| 80348 | 918,527 | 443,776 | $3.90M | |
| 80346 | 954,211 | 465,693 | $3.84M | |
| 83992 | 648,612 | 327,600 | $3.67M | |
| 80356 | 964,259 | 465,955 | $3.49M | |
| 80365 | 962,039 | 471,256 | $3.47M | |
| 80373 | 843,938 | 411,046 | $3.45M | |
| 80354 | 957,688 | 466,364 | $3.39M | |
| 80353 | 975,901 | 477,379 | $3.26M | |
| 80349 | 919,883 | 442,032 | $3.21M | |
| 80358 | 962,657 | 481,902 | $3.13M | |
| 80372 | 714,639 | 345,464 | $2.89M | |
| 80323 | 585,628 | 270,424 | $2.83M | |
| 80359 | 763,497 | 376,939 | $2.68M | |
| 80345 | 702,787 | 329,259 | $2.51M | |
| 80352 | 555,709 | 264,465 | $2.45M | |
| 80355 | 724,992 | 326,684 | $2.40M | |
| 80369 | 554,546 | 274,770 | $2.27M | |
| 80360 | 626,868 | 308,406 | $2.09M | |
| 80363 | 463,926 | 227,295 | $1.91M | |
| 80324 | 486,841 | 248,561 | $1.82M | |
| 80368 | 458,652 | 232,995 | $1.77M | |
| 80366 | 466,183 | 223,053 | $1.69M | |
| 80371 | 459,732 | 226,508 | $1.67M | |
| 80325 | 483,566 | 240,425 | $1.53M | |
| 81226 | 12,043 | 11,332 | $1.41M | |
| 80362 | 364,454 | 173,718 | $1.37M | |
| 80357 | 314,949 | 157,392 | $1.17M | |
| 81225 | 11,948 | 11,254 | $899K | |
| 84311 | 553,381 | 271,474 | $894K | |
| 80336 | 164,224 | 87,405 | $689K | |
| 80343 | 143,133 | 78,014 | $689K | |
| 82570 | 577,161 | 282,180 | $674K | |
| 80338 | 182,506 | 97,117 | $663K | |
| 80333 | 136,218 | 73,147 | $532K | |
| 81479 | Unlisted molecular pathology procedure | 42,139 | 11,180 | $454K |
| 83986 | 576,773 | 282,163 | $450K | |
| 81381 | 7,529 | 7,109 | $423K | |
| 80342 | 72,667 | 31,109 | $416K | |
| 81003 | 575,263 | 283,234 | $292K | |
| 81230 | 6,382 | 6,060 | $243K | |
| 81231 | 6,352 | 6,020 | $238K | |
| 80335 | 67,136 | 28,399 | $176K | |
| 81227 | 4,269 | 4,029 | $170K | |
| 81291 | 11,777 | 11,083 | $164K | |
| 80364 | 33,074 | 17,921 | $150K | |
| 80375 | 32,635 | 24,387 | $142K | |
| 80332 | 32,436 | 19,264 | $113K | |
| 80374 | 23,888 | 13,957 | $107K | |
| 81355 | 3,708 | 3,494 | $67K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1,459 | 221 | $58K |
| 80339 | 14,483 | 8,833 | $35K | |
| 87481 | 766 | 157 | $11K | |
| 87551 | 292 | 181 | $8K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 251 | 195 | $5K |
| 87640 | 251 | 195 | $5K | |
| 87500 | 250 | 170 | $4K | |
| 87653 | 237 | 183 | $4K | |
| 80326 | 949 | 866 | $3K | |
| 80370 | 639 | 588 | $2K | |
| 80337 | 74 | 70 | $304.90 | |
| 80334 | 111 | 103 | $304.84 | |
| 80344 | 97 | 92 | $294.58 | |
| G0479 | Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, tof, maldi, ldtd, desi, dart, ghpc, gc mass spectrometry), includes sample validation when performed, per date of service | 39 | 29 | $198.50 |
| 99080 | 61 | 40 | $0.00 | |
| 80301 | 30 | 13 | $0.00 |